Syneos Health to Present Actionable Commercial Insights Designed for Biopharmaceutical Companies at BIO International Convention

June 5, 2018
Company to Release 10th Annual Dealmakers’ Intentions Survey, Providing Forward-Looking Perspectives on Biopharmaceutical Licensing and Acquisitions

RALEIGH, N.C., June 05, 2018 (GLOBE NEWSWIRE) -- Syneos Health™ (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization combining a CRO (Contract Research Organization) and CCO (Contract Commercial Organization), will share new research and actionable commercial insights for the biotech industry during the BIO International Convention which runs June 4 - 7 in Boston, Massachusetts.

“Biopharmaceutical companies are facing mounting pressure to deliver profitable growth for investors, while speeding game-changing therapies to patients, in an environment of increasing scrutiny,” said Michelle Keefe, President, Commercial Solutions at Syneos Health. “This year at BIO, our goal is to bring novel solutions to these challenges forward based on new research and real world experience from our experts across the clinical and commercial continuum.”

Syneos Health will lead the following conversations at BIO, the world’s largest biotechnology industry gathering:

Dealmakers’ Intentions: 2018 Market Outlook
Tuesday, June 5, 2:30 p.m.3:45 p.m., Room 205ABC, Level 2

As large biopharmaceutical companies prune their portfolios and consider repatriation options, the expectation is running higher than ever for an uptick in M&A this year. The tension for CEOs in this environment is delivering a confident story about achieving profitable growth for investors while facing an increasingly complex marketplace. Join a highly distinguished panel of dealmakers who will explore the impact these market forces will have on biopharmaceutical companies as they strive to make the next big deal.

Moderator Neel Patel, Managing Director, Commercial Strategy & Planning at Syneos Health Consulting, will share findings from the 10th annual Syneos Health Dealmakers' Intentions Study. Based on a survey of industry executives and business development professionals, Dealmakers' Intentions provides insights into what will likely drive the industry's go-forward partnering and M&A efforts and the implications for dealmaking over the next year or more. Analysis will include year-over-year trends, deal metrics and broader M&A data.

Communicating Value Through the Eye of the Beholder
Wednesday, June 6, 11:00 a.m.12:00 p.m., Room 210A, Level 2

Value is in the eye of the beholder. Yet, the value of game-changing medicines is coming under greater scrutiny in the U.S. marketplace more than ever before. Companies are spending years developing drugs, only to arrive at commercialization disconnects with the very audiences they seek to serve. A well-defined value proposition for payers is no longer sufficient. Increasingly, developers must foster shared stakeholder expectations about the value of new medicines far sooner on the runway to commercialization.

Meg Alexander, Head of Reputation and Risk Management at Syneos Health will moderate a panel of leading biopharma executives, patient advocates and policy experts, providing perspectives on effective and compliant approaches to achieving shared views on value. Dialogue will reveal qualitative data on the resonance of different approaches to delivering value, from access initiatives to transparency pledges, offering actionable insights for today’s developers.

Follow Syneos Health on LinkedIn and Twitter to join the conversation and get a copy of the 2018 Dealmakers’ Intentions Survey.

About Syneos Health
Syneos Health (Nasdaq:SYNH) is the only fully integrated biopharmaceutical solutions organization. Our company, including a Contract Research Organization (CRO) and Contract Commercial Organization (CCO), is purpose-built to accelerate customer performance to address modern market realities. Created through the merger of two industry leading companies – INC Research and inVentiv Health – we bring together more than 21,000 clinical and commercial minds with the ability to support customers in more than 110 countries. Together we share insights, use the latest technologies and apply advanced business practices to speed our customers’ delivery of important therapies to patients. To learn more about how we are shortening the distance from lab to life® visit syneoshealth.com.

       
Contact:      
Investor Relations Contact:     Press/Media Contact:
Ronnie Speight     Danielle DeForge
Vice President, Investor Relations     Senior Director, External Communications
+1 919 745 2745     +1 202 210 5992
Investor.Relations@syneoshealth.com     danielle.deforge@syneoshealth.com

Primary Logo

Source: Syneos Health